Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.460
+0.300 (7.21%)
At close: Feb 11, 2026, 4:00 PM EST
4.450
-0.010 (-0.22%)
Pre-market: Feb 12, 2026, 4:59 AM EST
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
348.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | 48.63M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 113.34M |
| XOMA Royalty | 47.11M |
| X4 Pharmaceuticals | 33.98M |
| Foghorn Therapeutics | 24.52M |
| AC Immune | 5.48M |
AVIR News
- 27 days ago - Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha
- 7 weeks ago - Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript - Seeking Alpha
- 3 months ago - Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript - Seeking Alpha